Mersacidin, a new peptide antibiotic, was four-to eightfold less active (MIC for 90% of isolates, 8 ,ug/ml) than vancomycin, teicoplanin, or daptomycin against Staphylococcus aureus. Coagulase-negative staphylococci were inhibited by 8 ,ug/ml, and the MICs of mersacidin for hemolytic streptococci and Streptococcus pneumoniae were 4 to 8 ,ug/ml. The 
The increasing importance of gram-positive bacteria in hospital infections has caused a renewed investigation of compounds with activity against staphylococci and enterococci (1, 2, 4). Methicillin the activity of mersacidin were determined. Against 30 staphylococci, mersacidin was equally active at pH 5.5, 6.5, and 7.5. An inoculum of 107 CFU compared with an inoculum of 105 CFU did not increase the MICs-for methicillinsusceptible and methicillin-resistant S. aureus (eight isolates each). The MICs of mersacidin were within a dilution (error of the method) for staphylococci with Mueller-Hinton medium, Mueller-Hinton medium supplemented with 3% NaCl, brain heart infusion agar, and nutrient agar. The activity of mersacidin against S. aureus (methicillin susceptible and methicillin resistant) was similar under aerobic and anaerobic conditions. The addition of 5% sheep blood to agar did not alter the MICs for S. aureus, S. epidermidis, or E. faecalis. Mersacidin was bactericidal for staphylococci and streptococci, with MBCs within twofold of the MICs. However, there was an 8-to 16-fold difference in MBCs and MICs for E. faecalis and Enterococcus faecium.
Overall, mersacidin is appreciably less active than are the glycopeptides, vancomycin, and teicoplanin. It does inhibit methicillin-resistant S. aureus and organisms such as Corynebacteriumjeikeium. Ganguli et al. (3) reported that mersacidin was more effective in a mouse model of septicemia than was vancomycin, which was fourfold more active in vitro. Further investigation of this compound or possible chemical modification or both may yield an agent that can be used against problem gram-positive species.
